Fig. 1.

Genome-wide CRISPR screen overview. a A negative-selection screen was conducted in CAS9–PANC-1 cells. The cells were treated with 100 nM (IC₁₀) of gemcitabine from day 9 post transduction and collected for genomic DNA analysis on day 15. b Total reads, both mapped and unmapped. c Gini index (a measurement of inequality, with 1 being the most unequal) of the starting cell population and the three replicates of the dropout screen. d Candidate genes were identified after a dropout CRISPR screen (1) and the elimination of previously identified pan-essential genes (2). Resultant hits were further validated with pooled siRNA screens in PANC-1 and HPNE cells (3), and four individual siRNAs were deconvoluted and further validated in AsPC-1, Mia PaCa-2, and HPAF-II cells (4)